CNCR Loncar Cancer Immunotherapy ETF
CNCR Fund Description
CNCR tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.
CNCR Factset Analytics Insight
CNCR takes an approach to niche coverage within the health care sector. It provides equal-weighted exposure to about 30 companies of various sizes that have approved immunotherapy cancer drugs on the US or European markets or that are engaged in human clinical trials of such drugs. The fund seeks a holistic exposure to the immunotherapy space, specifically including companies with varying drug mechanisms. Equal-weighting of the securities draws attention to smaller companies with room to grow. This fund provides a unique option for investors placing a highly specialized bet on this space.
CNCR Summary Data
CNCR Portfolio Data
CNCR Index Data
CNCR Portfolio Management
CNCR Tax Exposures
CNCR Fund Structure
CNCR Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of CNCR. CNCR is rated a 3 out of 5.
CNCR Sector/Industry Breakdown
CNCR Top 10 Holdings[View All]
CNCR Economic Development
CNCR Performance Statistics
CNCR Benchmark Comparison Summary
CNCR Benchmark Comparison Market Cap Size